Welcome to our dedicated page for Moderna news (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna stock.
Moderna, Inc. (NASDAQ: MRNA) is a biotechnology company focused on mRNA medicines, with multiple approved vaccines and a broad clinical pipeline. The MRNA news page on Stock Titan aggregates company announcements, investor updates and regulatory developments so readers can follow how Moderna’s strategy and pipeline progress translate into real-world events.
Investors and observers can use this feed to track commercial updates on products such as Spikevax, mRESVIA and mNEXSPIKE, along with developments in late-stage respiratory programs like the seasonal influenza vaccine mRNA-1010, the flu/COVID combination vaccine mRNA-1083 and the Norovirus vaccine candidate mRNA-1403. News items often cover regulatory submissions and opinions from agencies including the U.S. Food and Drug Administration, the European Medicines Agency, Health Canada and others.
The page also surfaces pipeline and clinical trial news in oncology and rare diseases, including updates on mRNA-4157 (intismeran autogene), mRNA-4359, mRNA-3927 for propionic acidemia and mRNA-3705 for methylmalonic acidemia. Announcements related to partnerships, such as CEPI’s funding commitment for the H5 pandemic influenza vaccine candidate mRNA-1018, appear here as well.
In addition, the MRNA news feed includes financial results, guidance and capital structure updates, such as quarterly earnings releases, multi-year financial frameworks and information on facilities like the $1.5 billion credit agreement. Corporate items, including participation in healthcare conferences, Analyst Day presentations and shareholder meeting outcomes, are also reflected.
By reviewing this consolidated news stream, readers can see how Moderna’s respiratory vaccine franchise, oncology and rare disease programs, manufacturing expansion and financing decisions evolve over time, all based on the company’s own disclosures and related announcements.
On March 4, 2021, Moderna and IBM announced plans to collaborate on technologies to enhance COVID-19 vaccine management. Their pilot program aims to improve supply chain visibility and real-time tracking of vaccine distribution, utilizing artificial intelligence, blockchain, and hybrid cloud technologies.
The initiative includes vaccine management solutions for secure data sharing between governments and healthcare providers, as well as a Digital Health Pass that allows individuals control over their health information, facilitating verification of vaccination status.
Moderna (MRNA) reported remarkable financial results for Q4 and FY 2020, achieving total revenue of $571 million for Q4 and $803 million for the full year, driven by COVID-19 vaccine sales and grants, a significant increase from $14 million and $60 million in 2019, respectively. As of December 31, 2020, cash reserves surged to $5.25 billion, up from $1.26 billion a year prior. Notably, the company increased its 2021 global manufacturing goal for its COVID-19 vaccine from 600 million to 700 million doses, with plans for 1.4 billion doses by 2022. Moderna's pipeline now includes 24 mRNA development programs, with 13 in clinical studies.
Moderna (MRNA) announced new capital investments to enhance its manufacturing capacity for the COVID-19 vaccine, targeting a global output of approximately 1.4 billion doses in 2022, assuming a 100 μg dosage. The flexibility to produce vaccine boosters for emerging variants is also a focus. The company has already increased its 2021 production plan from 600 million to 700 million doses, with ongoing efforts to optimize operations for up to 1 billion doses this fiscal year. Approximately 60 million doses have been shipped globally, with expectations to fulfill government contracts in 2021.
Moderna (MRNA) has successfully manufactured clinical trial material for its variant-specific vaccine, mRNA-1273.351, targeting the SARS-CoV-2 B.1.351 variant. The doses have been shipped to the NIH for a Phase 1 clinical trial, which will assess the vaccine's ability to boost immunity against variants. Moderna is also exploring various booster strategies, including a multivalent booster candidate and additional doses of its existing vaccine. Initial data suggests its current vaccine provides neutralizing activity against variants, but further measures are necessary to enhance immunity.
Moderna (Nasdaq: MRNA) announced its participation in three upcoming virtual investor conferences. The events include the SVB Leerink 10th Annual Global Healthcare Conference on February 25, 2021, at 1:00 p.m. ET, the Cowen & Co. 41st Annual Health Care Conference on March 1, 2021, at 8:00 a.m. ET, and the Barclays Global Healthcare Conference on March 11, 2021, at 10:20 a.m. ET. Live webcasts will be available on Moderna's investor website and archived for 30 days post-event. Moderna has significantly advanced in mRNA technology, delivering vaccines and therapeutics for various diseases, including COVID-19.
Moderna, Inc. (Nasdaq: MRNA) has supplied 45.4 million doses of its COVID-19 Vaccine to the U.S. Government, with an additional 33.2 million doses in the final production stages. Approximately 25.5 million doses have been administered. Recent short-term delays in production are not expected to impact monthly delivery targets. The company anticipates meeting commitments for all ordered doses, expediting the delivery of the first 300 million doses across various timeframes. Production ramp-up continues, with expected monthly releases of 30-35 million doses for February and March, increasing to 40-50 million by July.
Moderna (Nasdaq: MRNA) has announced a new order commitment from the Canadian Government for an additional 4 million doses of its COVID-19 vaccine, bringing the total to 44 million doses. This increase highlights the Canadian Government's efforts to ensure vaccine availability for its citizens. Moderna's CEO, Stephane Bancel, expressed appreciation for this collaboration and emphasized the confidence in the vaccine's efficacy. Health Canada previously authorized the vaccine for individuals aged 18 and older, demonstrating continued regulatory support for Moderna's mRNA technology.
Moderna (Nasdaq: MRNA) announced the U.S. government's purchase of 100 million additional doses of its COVID-19 vaccine, totaling 300 million confirmed orders. With 41 million doses supplied to date, over 22 million Americans have received the vaccine. Moderna aims to deliver the first 100 million doses by Q1 2021 and the second by Q2 2021, leveraging its U.S. manufacturing capabilities. The company has secured agreements for over 631.5 million doses with various countries, reinforcing its role in the global fight against COVID-19.
Moderna, Inc. (Nasdaq: MRNA) announced that Qatar's Ministry of Public Health granted emergency use authorization for the COVID-19 Vaccine Moderna. This authorization is a significant milestone in the global fight against COVID-19, reflecting confidence in Moderna's mRNA vaccine. The approval is based on scientific evidence from a Phase 3 clinical study. The vaccine has already been authorized in multiple regions, including the U.S., EU, and UK. Moderna remains committed to working with global health agencies to expand its vaccine's availability.
Moderna, Inc. (Nasdaq: MRNA) announced supply agreements for its COVID-19 Vaccine Moderna with Taiwan (5 million doses) and Colombia (10 million doses). Deliveries are set to commence in mid-2021, pending regulatory approvals in both countries. The vaccine is based on mRNA technology and has received various authorizations globally. Moderna emphasizes collaboration with both governments in this effort.
FAQ
What is the current stock price of Moderna (MRNA)?
What is the market cap of Moderna (MRNA)?
